Abiopharma

(99% Neutral) GALECTO, INC. (GLTO) Announces New Board Appointment

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Hyperfine Announces First Peer-Reviewed Publication Demonstrating Significant Economic Benefits of Using the Swoop® AI-Powered Portable MRI System in Acute Hospital Care

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Nuwellis Announces Issuance of New U.S. Patent Supporting Advanced Safety Design for Pediatric Extracorporeal Therapy

NuCana plc (NCNA) Files Form 6-K

Astrana Health, Inc. to Participate in Upcoming Investor Conference

(10% Negative) MINERALYS THERAPEUTICS, INC. (MLYS) Announces Delay in Event Development Timeline Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(80% Positive) MILESTONE PHARMACEUTICALS INC. (MIST) Announces Enrollment Update for etripamil Due to Pandemic-Related Challenges, Patient Enrollment Issues, Safety Review, Efficacy Assessment

Butterfly Network, Inc. - Butterfly Network to Extend its Proprietary 3D Imaging Capabilities to Butterfly Garden Developers

Johnson & Johnson - Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

(99% Neutral) TRANSCODE THERAPEUTICS, INC. (RNAZ) Provides Update on Survival for Orthotopic Glioblastoma Models

Prenetics Global Ltd (PRE) Files Form 6-K

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Elanco Animal Health Inc. - Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference